This protocol addresses the management of patients with Wilson's disease who are also experiencing depression. The coexistence of these conditions presents a specific clinical challenge that warrants a structured, evidence-informed approach.
Depression is a recognised comorbidity in Wilson's disease. Evidence points to altered serotonergic neurotransmission as a contributing factor, making the choice of antidepressant class clinically meaningful in this population.
First-line management of depression in this setting involves an antidepressant from the SSRI class. The full structured regimen — including agent selection and therapeutic targets — is available in the complete protocol.
The primary therapeutic target is improvement and resolution of depressive symptoms.
The choice of SSRIs to treat depression in WD aligns with evidence of altered serotonergic neurotransmission in WD and SSRIs appear to be a reasonable choice as a first-line treatment.
SSRI/citalopram 20-40 mg/day or escitalopram 10-20 mg/day or sertraline 50-200 mg/g in first line.
View source ↗